N4 Pharma is a pre-clinical stage specialist pharmaceutical company developing Nuvec®, a unique novel silica nanoparticle technology with patented spiky structure designed to load, protect and deliver nucleic acids (siRNA/DNA/mRNA) intracellularly for use in as gene therapy, cancer therapeutics and vaccines. Established in 2014 and floated on the AIM stock market in May 2017.
Nuvec® is currently in the pre-clinical phase, available for licensing to pharmaceutical and biotech partners for nucleic acid product development and is designed to overcome some of the drawbacks of existing delivery systems.
Learn more
Latest news and updates
Article: Could new-generation silica nanoparticles be the next big thing in siRNA delivery systems for cancer treatment?
In our latest article, we look at how Nuvec® offers an alternative to current drug delivery approaches for small interfering RNA (siRNA). Not only is Nuvec® particularly suited to chemical modification, allowing the addition of target [...]
The data – evidence based results
As a result of recently completed initial testing in vitro on loaded Nuvec® with two generic siRNA probes, N4 Pharma has created an infographic outlining the key results and detailing how Nuvec® works to deliver [...]
Article: Deagglomeration of DNA nanomedicine carriers using controlled ultrasonication
Ultrasound sonication is a well-established mechanism for the deagglomeration of particle materials in dispersion. In this recently published paper, the National Physical Laboratory investigates the deagglomeration of Nuvec® silica particles with and without the presence [...]